SAN FRANCISCO, CA--(Marketwire - Nov 17, 2011) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that Sarah Noonberg, M.D., Ph.D. has been promoted to vice president of clinical development. Dr. Noonberg joined Medivation in 2007.

"This promotion is a reflection of Sarah's significant contributions to Medivation," said Lynn Seely, M.D., chief medical officer of Medivation. "Sarah will play a critical leadership role in our clinical organization as we work to advance new molecules into the clinic to support Medivation's planned pipeline growth."

Prior to joining Medivation, Dr. Noonberg held clinical positions of increasing seniority at Chiron Corporation, where she led the late phase clinical development of multiple compounds in infectious disease and pulmonary indications. Since joining Medivation in 2007, she has successfully led studies in all phases of development. Dr. Noonberg earned her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley and her B.S. at Dartmouth College. Dr. Noonberg is a board-certified internist and completed her residency at the Johns Hopkins Hospital.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at [ www.medivation.com ].